San Diego-primarily based Viking Therapeutics marked alone as a serious competitor within the weight loss drug current market in February immediately after revealing promising information from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified being a weekly injection